Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.

Also called NCT05624190

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 256 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05624190
Other papers using this trial's data
  • Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial JAMA, 2025-08-19 DOI, PubMed 40616323, PMC12228980 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05624190. Randomized; single masking; primary purpose treatment. Start 2023-02-16 (actual); primary completion 2024-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization
Acronym
ANGEL-TNK
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)
Intervention (Other)
Best Medical Management
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05624190
Content hash
2b5b75339334c21ae21cdebebb8c6fc6ea4cb187f5db7945464fce93b9f82731